Proceeding contribution from Paul Burstow (Liberal Democrat) in the House of Commons on Tuesday, 4 November 2008. It occurred during Ministerial statement on NHS Patients (Access to Medicines).
NHS Patients (Access to Medicines)
Speedier NICE appraisal decisions are essential but they are not sufficient. We also need more transparency and accountability in NICE decisions. In the light of the Law Lords' decision to refuse permission to NICE to go to appeal on the dementia drug case decision, will the Secretary of State now put it beyond doubt that he expects NICE to place all the models it uses in respect of decisions on appraisals into the public domain?
Secondary information
- Type
- Proceeding contribution
- Reference
- 482 c146
- Session
- 2007-08
- Chamber / Committee
- House of Commons chamber
- Subjects
- Access Finance Fees and charges Drugs Private sector NHS Medical treatments Patients Payments National Institute for Health and Care Excellence Consequences of Additional Private Drugs for NHS Care Review
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2023-12-16 01:23:33 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_505651
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_505651
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_505651